Lonidamine and radiotherapy in head and neck cancers. A pilot study.
The tolerance and antitumor activity of Lonidamine combined with radiotherapy were studied on 40 patients with head and neck cancer and compared with a historical control group. Lonidamine was well tolerated. 26 and 17 complete responses were seen in the Lonidamine-treated group and in the historical control group, respectively.